Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for MDA5-positive dermatomyositis with interstitial lung disease
ChiCTR2100047938Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of baricitinib in dermatomyositis (DM), amyopathic dermatomyositis (ADM) and interstitial lung disease (ILD), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: 6-month survival rate and Lung HRCT score. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
dermatomyositis (DM)amyopathic dermatomyositis (ADM)interstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR2100047938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047938.